The invention belongs to the field of
analytical chemistry and clinical
medicine and relates to a
plasma metabolization micromolecule marker related to the human non-small-
cell lung cancer and an application of the
plasma metabolization micromolecule marker. The
plasma metabolization micromolecule marker related to the human non-small-
cell lung cancer is one or more of cortisol,
corticosterone and 4-methoxyphenylacetic acid. The plasma metabolization micromolecule marker is prepared from cortisol,
corticosterone and 4-methoxyphenylacetic acid. The content range (95%
confidence interval) of cortisol is 0.00018-0.00067, the content range (95%
confidence interval) of
corticosterone is 0.000029-0.00010, the content range (95%
confidence interval) of 4-methoxyphenylacetic acid is 0.000015-0.000022, and
metabolite can prompt occurrence of tumors within the ranges. The horizontal range, corresponding to a
normal group, of cortisol is 0.0030-0.0037, the horizontal range, corresponding to the
normal group, of corticosterone is 0.00044-0.00056, and the horizontal range, corresponding to the
normal group, of 4-methoxyphenylacetic acid is 7.39 E-07-2.09 E-06. The plasma metabolization micromolecule marker is a novel biomarker, compared with a traditional
protein biomarker, the relevance between the marker and the
disease outcome is higher, and the plasma metabolization micromolecule marker is stable, minimally invasive, easy to detect and accurate in quantitation.